In a March 11 note, Roth Capital Partners analyst Taz Koujalgi maintained a “Neutral” rating and $90.00 price target on Fortinet (Fortinet Stock Quote, Chart, News, Analysts, Financials NASDAQ:FTNT) following the company’s investor briefing held alongside its Accelerate conference in Las Vegas.
Koujalgi said the company highlighted growth opportunities across operational technology security, SASE, SD-WAN and AI security, supported by its integrated platform built on the FortiOS operating system and proprietary FortiASIC chips.
Fortinet estimates its core markets — Secure Networking, Unified SASE and SecOps — represent a combined $310-billion total addressable market. The company said it is gaining share across all three segments, with 2025 billings growth of 12% in Secure Networking, 24% in Unified SASE and 22% in SecOps.
Koujalgi added that rising AI adoption is expanding the cybersecurity attack surface, creating additional demand for infrastructure protection and security software.
Fortinet said its product suite can secure AI infrastructure, models and applications, and pointed to a partnership with NVIDIA Corporation aimed at securing Nvidia’s BlueField-3 data processing units.
The company also reiterated its long-term financial targets from its 2024 Analyst Day, including billings and revenue growth above 12% CAGR over the next three to five years, operating margins above 30%, and free cash flow margins in the mid-to-high 30% range.
-30-
RBC economist Abbey Xu said Canadian travel demand is not weakening so much as shifting away from the United States and… [Read More]
Roth Capital Markets analyst Philip Shen maintained his “Buy” rating and $55.00 target on Enphase Energy (Enphase Energy Stock Quote,… [Read More]
On BNN Bloomberg Market Call on April 6, Scotia Wealth Management portfolio manager Stan Wong named Taiwan Semiconductor Manufacturing (Taiwan… [Read More]
Ventum Capital Markets analyst Amr Ezzat reiterated his “Buy” rating and $8.70 target on Zedcor (Zedcor Stock Quote, Chart, News,… [Read More]
Research Capital analyst Andre Uddin maintained his “Speculative Buy” rating and US$ 5.50 target on NervGen Pharma (NervGen Pharma Stock Quote, Chart,… [Read More]
In an April 8 note, Paradigm Capital analyst Scott McAuley maintained his “Speculative Buy” rating on Perimeter Medical Imaging AI… [Read More]